ProMIS Neurosciences, Inc. (23J0.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Eugene W. Williams | Co-Founder & Chairman | 242.28k | -- | 1959 |
| Mr. Neil K. Warma M.B.A. | CEO, President, Compliance Officer & Director | 35.24k | -- | 1963 |
| Dr. Neil R. Cashman M.D. | Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director | 316.86k | -- | 1952 |
| Mr. Daniel E. Geffken M.B.A. | Chief Financial Officer | 77.79k | -- | 1957 |
| Dr. Johanne Kaplan Ph.D. | Chief Development Officer | 227.41k | -- | 1960 |
| Dr. David Wishart Ph.D. | Chief Physics Officer | -- | -- | -- |
| Mr. Dennis Chen Ph.D. | Head of Manufacturing & Senior Consultant | -- | -- | -- |
| Dr. Larry Douglas Altstiel M.D., Ph.D. | Chief Medical Officer | -- | -- | 1950 |
ProMIS Neurosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 7
Description
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Corporate Governance
Upcoming Events
May 12, 2025 at 10:59 AM UTC - May 16, 2025 at 12:00 PM UTC
ProMIS Neurosciences, Inc. Earnings Date
Recent Events
Recent Events Information Not Available